SCHEMBL4414448

SCHEMBL4414448

CC(C)(C)OC(=O)N1CCC(c2nc(-c3ccc(Br)cc3)no2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.56
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
HDAC4 P56524 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
LMNA P02545 3/20 0.52
TSHR P16473 3/20 0.52
HDAC6 Q9UBN7 1/20 0.50
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48
TUBB8 Q3ZCM7 1/20 0.48
TUBA3E Q6PEY2 1/20 0.48
TUBA1A Q71U36 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4423384 0.90 GPR119 (0.59) GPR119NPC1RAB9AHDAC4SMN1; SMN2
SCHEMBL4420449 0.89 LMNA (0.61) GPR119L3MBTL1HDAC4SMN1; SMN2LMNA
SCHEMBL4414338 0.89 GPR119 (0.56) GPR119HDAC4SMN1; SMN2LMNATSHR
SCHEMBL12580564 0.89 HDAC4 (0.56) GPR119HDAC4SMN1; SMN2LMNATSHR
SCHEMBL4419288 0.89 LMNA (0.59) GPR119L3MBTL1HDAC4SMN1; SMN2LMNA
SCHEMBL2901393 0.89 TUBB4A (0.58) GPR119HDAC4SMN1; SMN2LMNATSHR
SCHEMBL31260537 0.89 HDAC4 (0.56) GPR119HDAC4SMN1; SMN2LMNATSHR
SCHEMBL1653518 0.89 TUBB4A (0.60) GPR119HDAC4SMN1; SMN2LMNATSHR
SCHEMBL4415594 0.88 HTT (0.57) GPR119HDAC4SMN1; SMN2LMNATSHR
SCHEMBL390646 0.88 GPR119 (0.67) GPR119HDAC4SMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US claimed
CN-116178361-A Preparation of piperidine bisoxadiazole and piperidine amino thiazole substituted antitumor curcumenol derivatives and application thereof in antitumor 华东理工大学 2023-05-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885NPC1 620/4885RAB9A 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.